Regeneron Pharmaceuticals Inc. has announced positive results from two Phase 3 trials evaluating its first-in-class investigational allergen-blocking antibodies for cat and birch allergies. Both trials, which focused on allergen-challenge scenarios involving moderate-to-severe allergies, achieved their primary and key secondary endpoints. The trials demonstrated that a single dose of the allergen-specific antibody blockers significantly reduced allergy symptoms compared to a placebo. No serious adverse events or trial discontinuations were reported. Data from these trials will be presented at an upcoming medical conference and will support further Phase 3 development, planned to commence by the end of the year.